CD274 and gastric cancer: The relative lag in immunological research and limited therapeutic options contribute to the underlying reasons for this phenomenon in gastric cancer, which currently only includes human epidermal growth factor receptor 2 (HER‐2) and programmed death ligand 1 (PD‐L1)‐targeted drugs.